首页> 外文OA文献 >Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations

【2h】

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations

机译：内源性CD4 + T细胞识别肺癌患者的新抗原，包括复发性致癌kras和erbb2（Her2）驾驶员突变

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Joshua R. Veatch; Brenda L. Jesernig; Julia Kargl; Matthew Fitzgibbon; Sylvia M. Lee; Christina Baik; Renato Martins; A. McGarry Houghton; Stanley R. Riddell;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Endogenous CD4(+) thorn T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations [J] . Veatch Joshua R., Jesernig Brenda L., Kargl Julia, Cancer immunology research. . 2019,第6期

机译：内源性CD4（+）刺T细胞识别肺癌患者的新抗原，包括复发性致癌kras和erbb2（Her2）驾驶员突变
2. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients [J] . JiangL., HuangJ., MorehouseC., Cancer genetics . 2013,第9a10期

机译：非小细胞肺癌患者大肠癌患者的低频KRAS突变和致癌驱动因素中的多个突变
3. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. [J] . Varella Garcia M, Mitsudomi T, Yatabe Y, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2009,第3期

机译：复发性非小细胞肺癌术后的EGFR和HER2基因组学获益：对吉非替尼治疗效果的影响以及与日本队列中的EGFR和KRAS突变相关。
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer [O] . Toshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, 2020

机译：HER2-D16致癌司机突变在EGFR突变阳性非小细胞肺癌中赋予Osimertinib抗性
7. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients [O] . Jiang Liyan, Huang Jiaqi, Morehouse Chris, 2013

机译：非小细胞肺癌患者大肠癌患者的低频KRAS突变和致癌驱动因素中的多个突变

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations

著录项

引文网络

相似文献

相关主题

期刊订阅